Recession Worries? Heres 1 of the Best Dividend Stocks for Turbulent Times
J.P. Morgan stated last month that it believes there is a 60% chance of a recession in 2025 due to…
44,960$
0,72%
Echtzeit-Aktienkurs Cerevel Therapeutics Hld. Inc.
Bid:
Ask:
Nachrichten zur Cerevel Therapeutics Hld. Inc. Aktie
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights – ABBV
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings,…
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress…
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors – Contact Levi & Korsinsky
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings,…
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
2 No-Brainer Dividend Stocks to Buy With $250 in 2025
When it comes to dividend investing, there are two basic paths you can take. You could seek out businesses that…
2 Excellent Dividend Stocks to Buy on the Dip
AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) have a lot in common. They are both leading drugmakers and have strong…
1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever
This will go down in history as an incredible year for stocks. The S&P 500 hit a new all-time high…
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Last year, pharmaceutical giant AbbVie (NYSE: ABBV) lost patent exclusivity for its biggest cash cow, immunology medicine Humira. The drugmaker…
AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials
AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat…
Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies in 2024
Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking…
CEREVEL NEWS NOTIFICATION: BFA Law Alerts Cerevel (Nasdaq: CERE) Shareholders of Investigation into the $45 Merger Offer, Contact the Firm About Your Rights
NEW YORK, June 08, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating…
CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation into the $45 Merger Offer
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating…
CERE (NASDAQ) ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation; Contact BFA Law to Discuss Your Rights
NEW YORK, May 25, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating…
BREAKING CEREVEL INVESTIGATION: BFA Law Is Investigating the $45 Per CERE (Nasdaq) Share Offer by AbbVie, Contact the Firm for Details
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Bleichmar Fonti & Auld LLP is investigating the merger between…